Article

A six-gene signature predicts survival of patients with localized pancreatic ductal adenocarcinoma.

Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
PLoS Medicine (Impact Factor: 14). 07/2010; 7(7):e1000307. DOI: 10.1371/journal.pmed.1000307
Source: PubMed

ABSTRACT Pancreatic ductal adenocarcinoma (PDAC) remains a lethal disease. For patients with localized PDAC, surgery is the best option, but with a median survival of less than 2 years and a difficult and prolonged postoperative course for most, there is an urgent need to better identify patients who have the most aggressive disease.
We analyzed the gene expression profiles of primary tumors from patients with localized compared to metastatic disease and identified a six-gene signature associated with metastatic disease. We evaluated the prognostic potential of this signature in a training set of 34 patients with localized and resected PDAC and selected a cut-point associated with outcome using X-tile. We then applied this cut-point to an independent test set of 67 patients with localized and resected PDAC and found that our signature was independently predictive of survival and superior to established clinical prognostic factors such as grade, tumor size, and nodal status, with a hazard ratio of 4.1 (95% confidence interval [CI] 1.7-10.0). Patients defined to be high-risk patients by the six-gene signature had a 1-year survival rate of 55% compared to 91% in the low-risk group.
Our six-gene signature may be used to better stage PDAC patients and assist in the difficult treatment decisions of surgery and to select patients whose tumor biology may benefit most from neoadjuvant therapy. The use of this six-gene signature should be investigated in prospective patient cohorts, and if confirmed, in future PDAC clinical trials, its potential as a biomarker should be investigated. Genes in this signature, or the pathways that they fall into, may represent new therapeutic targets. Please see later in the article for the Editors' Summary.

0 Bookmarks
 · 
230 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Improved usage of the repertoires of pancreatic ductal adenocarcinoma (PDAC) profiles is crucially needed to guide the development of predictive and prognostic tools that could inform the selection of treatment options. Using publicly available mRNA abundance datasets, we performed a large retrospective meta-analysis on 466 PDAC patients to discover prognostic gene signatures. These signatures were trained on two clinical cohorts (n = 70), and validated on four independent clinical cohorts (n = 246). Further validation of the identified gene signature was performed using quantitative real-time RT-PCR. We identified 225 candidate prognostic genes. Using these, a 36-gene signature was discovered and validated on fully independent clinical cohorts (hazard ratio (HR) = 2.06, 95% confidence interval (CI) = 1.51 to 2.81, P = 3.62 × 10(-6), n = 246). This signature serves as a good alternative prognostic stratification marker compared to tumour grade (HR = 2.05, 95% CI = 1.45 to 2.88, P = 3.18 × 10(-5)) and tumour node metastasis (TNM) stage (HR = 1.13, 95% CI = 0.66 to 1.94, P = 0.67). Upon multivariate analysis with adjustment for TNM stage and tumour grade, the 36-gene signature remained an independent prognostic predictor of clinical outcome (HR = 2.21, 95% CI = 1.17 to 4.16, P = 0.01). Univariate assessment revealed higher expression of ITGA5, SEMA3A, KIF4A, IL20RB, SLC20A1, CDC45, PXN, SSX3 and TMEM26 was correlated with shorter survival while B3GNT1, NOSTRIN and CADPS down-regulation was associated with poor outcome. Our 36-gene classifier is able to prognosticate PDAC independent of patient cohort and microarray platforms. Further work on the functional roles, downstream events and interactions of the signature genes is likely to reveal true molecular candidates for PDAC therapeutics.
    Genome Medicine 12/2014; 6(12):105. · 4.94 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Die molekularen Veränderungen in soliden und zystischen Pankreastumoren sind in den letzten Jahren zunehmend charakterisiert worden. Das duktale Pankreaskarzinom zeichnet sich durch zahlreiche Punktmutationen und z. T. auch Deletionen und Amplifikationen von Genen aus, welche mindestens 13 tumorrelevante zelluläre Prozesse betreffen. Neben den 4 führenden Alterationen in den KRAS-, p53-, CDKN2a- und SMAD4-Genen gibt es zahlreiche Treibermutationen mit geringer Frequenz. Fortschritte sind bei der Subklassifikation der duktalen Pankreaskarzinome aufgrund von Genexpressionssignaturen zu verzeichnen, wobei ein KRAS-getriebener klassischer und ein KRAS-unabhängiger quasimesenchymaler Subtyp beschrieben wurden. Durch die Analyse von mRNA- und MicroRNA-Expressionsprofilen aus Punktaten ist die Grundlage für eine präoperative Artdiagnose von Pankreasraumforderungen geschaffen worden. Die 4 häufigsten zystischen Pankreastumoren besitzen z. T. entitätsspezifische genetische Veränderungen, wie z. B. GNAS-Mutationen in intraduktal papillär muzinösen Neoplasien, β-Catenin-Mutationen in solidpseudopapillären Neoplasien und VHL-Punktmutationen oder „loss of heterozygosity“ in serösen Zystadenomen. Da die Zystenflüssigkeiten aus zystischen Pankreastumoren diagnostisch verwertbare DNA enthalten, besteht die Möglichkeit einer verbesserten präoperativen Unterscheidung der zystischen Pankreastumoren aufgrund von Mutationsanalysen. Zusätzlich zu DNA-basierten Verfahren gibt es viel versprechende Ansätze für die präoperative Unterscheidung benigner und prämaligner/maligner zystischer Pankreastumoren aufgrund von MicroRNA-Signaturen. In den letzten Jahren wurden wichtige Fortschritte bei der molekularen Charakterisierung der Pankreastumoren und hinsichtlich der Methodik der präoperativen molekularen Analyse erzielt. Diese Ergebnisse geben uns Hoffnung, dass präoperative molekulare Verfahren die prognostische/therapeutische Stratifizierung duktaler Pankreaskarzinome und eine sichere präoperative Diagnostik benigner zystischer Pankreastumoren in der Zukunft ermöglichen. Abstract Genetic alterations of solid and cystic tumors of the pancreas have been increasingly more characterized over the last few years. Pancreatic ductal adenocarcinoma (PDAC) carries numerous point mutations and, to a lesser extent, deletions and amplifications of genes that are associated with at least 13 tumor relevant signalling pathways and processes. Besides the four common driver mutations in the KRAS, p53, CDKN2a and SMAD4 genes there are a number of low frequency driver mutations. The classification of PDAC subtypes has benefited from recent analyses of transcriptional profiles that revealed a classical KRAS driven and a KRAS independent quasi-mesenchymal subtype. The analyses of mRNA and miRNA expression profiles of fine needle aspirates serve as a basis for reliable preoperative diagnosis of pancreatic masses. The four most common cystic pancreatic tumors bear tumor-specific genetic alterations, such as GNAS mutations in intraductal papillary mucinous neoplasms, β-catenin mutations in solid pseudopapillary neoplasms and VHL mutations or loss of heterozygosity in serous cystadenoma. Recovery of DNA from aspirates of cyst fluids enables an improved preoperative management of cystic pancreatic tumors by mutational analysis. In addition to the analysis of DNA there are promising approaches in distinguishing benign and premalignant/malignant cystic tumors by evaluating miRNA profiles. In recent years much progress has been made in molecular genetic characterization and preoperative evaluation of pancreatic tumors. Hopefully these results will contribute to prognostic and therapeutic stratification of PDAC and to a reliable preoperative diagnostics of benign cystic pancreatic tumors in the future.
    Der Pathologe 11/2013; 34(S2):214-220. · 0.64 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose: Expression of CBL, an ubiquitin ligase, is decreased in 60% of human pancreatic ductal adenocarcinomas (PDACs) and is associated with shorter overall survival. We sought to determine how low CBL directly contributes to clinically more aggressive PDAC. Experimental Design: Human PDACs were stained for CBL, pEGFR, and EGFR. CBL-low was modeled in PDAC cells (Panc-1, L3.6pl, AsPC-1) via transient transfection (siRNA) or stable knockdown (shRNA). Cell viability and apoptosis were measured by MTT assays and FACS. Immunoblot and a phospho-receptor tyrosine kinase (pRTK) array were used to probe signal transduction. NOD-scid-IL2Rγ(null) mice were subcutaneously implanted with PDAC or PDAC(CBL-low) cells on opposite flanks and treated with gemcitabine ± erlotinib for ≥4 weeks. Results: There was an inverse correlation between CBL and pEGFR protein expression in 12 of 15 tumors. CBL knockdown increased PDAC resistance to gemcitabine and 5-FU by upregulating pEGFR (Y1068), pERK, and pAKT. A pRTK array of PDAC(CBL-low) cells revealed additional activated tyrosine kinases but all to a much lower magnitude than EGFR. Increased chemoresistance from low CBL was abrogated by the EGFR inhibitor erlotinib both in vitro and in vivo. Erlotinib + gemcitabine treated PDAC(CBL-low) cells exhibited greater apoptosis by cleaved PARP, Caspase 3 and Annexin V/PI. Conclusions: Low CBL causes chemoresistance in PDAC via stress-induced EGFR activation that can be effectively abrogated by EGFR inhibition. These results suggest that dysregulation of ubiquitination is a key mechanism of EGFR hyperactivation in PDAC and that low CBL may define PDAC tumors likely to respond to erlotinib treatment.
    Journal of Surgical Research 10/2014; 21(1). · 2.12 Impact Factor

Full-text (2 Sources)

Download
59 Downloads
Available from
May 21, 2014